CORP
2011
COlchicine for Recurrent Pericarditis
In 120 patients with a first recurrence of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy halved further recurrence at 18 months compared with placebo.
Result
- Absolute difference
- 31 points
- NNT
- 4
relative risk reduction0.5695% CI 0.27-0.73
Absolute difference and NNT are derived from the event rates.
Also reported: NNT 3). Side-effect and withdrawal rates similar.
- Subtopic
- Recurrent pericarditis
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2025 Myo/Pericarditis
- Source
- Imazio M, Brucato A, Cemin R, et al. Ann Intern Med. 2011;155(7):409-414.doi 10.7326/0003-4819-155-7-201110040-00359
Discussion & critique
Small, single-country and restricted to a first recurrence of non-bacterial, non-neoplastic aetiology. It was the first properly blinded randomised demonstration that colchicine prevents relapse and, with ICAP and CORP-2, underpins the class-I recommendation.